About
Antibody for stroke
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (24)
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
658
By Phase
PHASE2/PHASE3: 1PHASE2: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05070260Lead Sponsor
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
PHASE2/PHASE3Completed
438 participants
Started: Sep 23, 2021 · Completed: Apr 30, 2024
NCT04659109Lead Sponsor
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
PHASE2Completed
60 participants
Started: Dec 16, 2020 · Completed: Aug 6, 2021
NCT03803007Lead Sponsor
Acute Ischemic Stroke Interventional Study
PHASE1/PHASE2Completed
160 participants
Started: Mar 6, 2019 · Completed: Sep 27, 2021
Locations (1)
Headquarters
Paris, France
Map
Loading map...